Keloid Treatment Market

Keloid Treatment Market Research Report: Size, Share, Trend Analysis By Product (Elastic Wraps, Ointment), by Treatment (Radiation Therapy, Cry Therapy, Surgical Treatment, Laser Treatment, Laser Treatment, Interferon), by End-User (Hospitals and Others), Regions ) - Growth Outlook & Industry Forecast 2025 To 2035
ID: MRFR/Pharma/5340-HCR
90 Pages
Rahul Gotadki
Last Updated: July 28, 2026
Keloid Treatment Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)6.67%
2024 Market Size$ 3.27 Million
2025 Market Size$ 3.53 Million
2035 Market Size$ 6.69 Million
Key Players
Companies such as Medytox
Keloid Solutions
Sientra
Revance Therapeutics
Bausch Health
MediWound
Trends
  • Personalized Treatment Approaches
  • Technological Advancements in Treatment
  • Integration of Digital Health Solutions
Opportunities
  • Market Growth Projections
  • Rising Cosmetic Procedures
  • Rising Prevalence of Keloids
Request Free Sample

Keloid Treatment Market Summary

Global Keloid Treatment Market Size was valued at USD 3.27 Million in 2024 & the market is projected to grow from USD 3.53 Million in 2025 to USD 6.69 Million by 2035, registering a CAGR of 6.67% during the forecast period 2025–2035. North America led the market with over 45.87% share, generating around USD 1.5 Million in revenue.
 
The rising incidence of surgical procedures, traumatic skin injuries, and growing demand for aesthetic scar management are driving the Keloid Treatment Market. Increasing awareness, early diagnosis, and adoption of advanced minimally invasive therapies continue improving treatment outcomes and supporting market expansion.
 
According to the WHO Data Portal, more than 234 million major surgical procedures are performed globally each year, increasing the population at risk for postoperative scar formation and supporting long-term demand for effective keloid treatment solutions.

Key Market Trends & Highlights

The Keloid Treatment Market is experiencing a shift towards personalized and technologically advanced treatment options.

  • North America led the Keloid Treatment Market, accounting for over 45.87% of global revenue in 2024.
  • Europe Keloid Treatment Market was valued at USD 0.9 million in 2024, representing the second-largest regional market with a 27.52% share.
  • Surgical excision accounted for approximately 39% of treatment demand owing to its effectiveness in permanent keloid removal and recurrence management.
  • Medium-sized keloids represented nearly 48% of treated cases, supported by established clinical protocols and increasing patient awareness.
  • Healthcare providers contributed approximately 73% of end-user demand through specialized dermatology, reconstructive surgery, and comprehensive scar management services.
  • WHO estimates more than 234 million major surgical procedures are performed globally each year, sustaining long-term demand for postoperative keloid treatment.

Market Size & Forecast

2024 Market Size 3.27 (USD Million)
2035 Market Size 6.69 (USD Million)
CAGR (2025 - 2035) 6.67%

Major Players

Companies such as Medytox (KR), Keloid Solutions (US), Sientra (US), Revance Therapeutics (US), Bausch Health (CA), MediWound (IL), Hugel (KR), Galderma (CH), Evolus(US) are some of the major participants in the market.

Keloid Treatment Market Drivers

Market Growth Projections

The Global Keloid Treatment Market Industry is projected to experience steady growth, with estimates indicating a market size of 1.73 USD Billion in 2024 and a potential increase to 1.9 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate (CAGR) of 0.86% from 2025 to 2035. Such projections highlight the ongoing demand for keloid treatments and the industry's responsiveness to emerging trends and technologies. The market's expansion reflects broader healthcare trends, including a focus on personalized medicine and improved patient care.

  • According to the World Bank, rising healthcare expenditure across developed and emerging economies continues supporting investment in dermatology services, advanced wound care, and innovative scar management technologies.

Rising Cosmetic Procedures

The rise in cosmetic procedures is another driver for the Global Keloid Treatment Market Industry. As more individuals undergo surgeries for aesthetic enhancements, the likelihood of keloid formation increases. This trend is particularly pronounced in regions where cosmetic surgery is gaining popularity. Patients seeking to minimize the appearance of keloids post-surgery are driving demand for effective treatment solutions. The market's growth is expected to be sustained as the beauty industry continues to expand, with keloid treatments becoming an integral part of post-operative care.

  • According to PubMed, the continued increase in cosmetic and reconstructive surgical procedures worldwide has expanded the need for postoperative scar prevention and keloid treatment interventions.

Rising Prevalence of Keloids

The Global Keloid Treatment Market Industry is experiencing growth due to the rising prevalence of keloids, which are often associated with surgical scars, acne, and trauma. As awareness increases regarding the condition, more individuals seek treatment options. In 2024, the market is projected to reach 1.73 USD Billion, reflecting a growing demand for effective therapies. This trend is particularly evident in regions with high rates of skin injuries, such as urban areas where surgical procedures are common. The increasing incidence of keloids is likely to drive innovation in treatment modalities, further expanding the market.

  • According to IHME, skin and subcutaneous diseases remain a significant contributor to the global non-fatal disease burden, supporting increasing demand for specialized dermatological treatment services.

Growing Awareness and Education

The Global Keloid Treatment Market Industry benefits from increasing awareness and education about keloids among both healthcare professionals and patients. Educational campaigns and resources provided by dermatological associations are helping to demystify keloids, leading to earlier diagnosis and treatment. This heightened awareness is crucial, as it encourages individuals to seek medical advice sooner, thereby increasing treatment uptake. As more patients become informed about their options, the market is likely to see a steady rise in demand for keloid treatments, contributing to a projected CAGR of 0.86% from 2025 to 2035.

  • According to PubMed, increased dermatology education and clinical awareness have improved early recognition of abnormal scar formation, encouraging timely intervention and better treatment outcomes for patients with keloids.

Increased Research and Development

Increased investment in research and development is propelling the Global Keloid Treatment Market Industry forward. Pharmaceutical companies and research institutions are focusing on understanding the underlying mechanisms of keloid formation, which may lead to the discovery of novel therapeutic agents. This emphasis on R&D is likely to yield new treatment options that are more effective and tailored to individual patient needs. As the market evolves, the introduction of innovative therapies could significantly alter the treatment landscape, enhancing patient satisfaction and outcomes.

  • According to the World Bank, expanding investments in biomedical research and healthcare innovation continue supporting development of novel dermatological therapies and precision treatment technologies.

Advancements in Treatment Technologies

Innovations in treatment technologies are significantly influencing the Global Keloid Treatment Market Industry. New methods, such as laser therapy, cryotherapy, and intralesional injections, are being developed and refined, offering patients more effective options. These advancements not only enhance treatment efficacy but also reduce recovery times and side effects. As a result, healthcare providers are increasingly adopting these technologies, contributing to market growth. The anticipated increase in market size to 1.9 USD Billion by 2035 underscores the potential of these advancements to reshape treatment paradigms and improve patient outcomes.

  • According to PubMed, advances in laser therapy, cryotherapy, corticosteroid injections, and combination treatment approaches have demonstrated improved efficacy and reduced recurrence rates in keloid management.

Market Segment Insights

By Treatment Type: Surgical Excision (Largest) vs. Laser Therapy (Fastest-Growing)

In the Keloid Treatment Market, the segment is diversified into various treatment types, including Surgical Excision, Intralesional Steroid Injection, Cryotherapy, Laser Therapy, and Radiation Therapy. Surgical Excision holds the largest market share of 39% owing to its effectiveness in permanently removing keloids, appealing to patients seeking permanent solutions. Other treatments like Intralesional Steroid Injection and Cryotherapy play essential roles but capture smaller shares, primarily providing alternatives for patients desiring less invasive approaches or lower-cost options.

Medytox (KR) continues advancing aesthetic treatment innovation and regenerative medicine research, supporting comprehensive scar management strategies alongside surgical interventions.

By Keloid Size: Medium Keloids (Largest) vs. Small Keloids (Fastest-Growing)

In the Keloid Treatment Market, the distribution of keloid sizes reveals that medium keloids hold the largest share of 48% among the various segments. Their prevalence can be attributed to a combination of genetic factors and the frequency of injury in the population. Small keloids, while currently representing a smaller proportion of the market, are quickly gaining traction as an emerging trend in keloid treatments. The increasing number of cosmetic procedures and awareness regarding keloid treatments has heightened interest in this segment. As the keloid treatment market evolves, medium keloids continue to dominate due to their established treatment protocols and patient familiarity with existing options. Meanwhile, small keloids have become the fastest-growing segment, driven by increasing demand for minimally invasive treatments and innovative therapies. The rise of telemedicine and online consultations has also made it easier for patients to seek treatment for these smaller keloids, further propelling this segment's growth.

Keloid Solutions (US) continues expanding specialized scar treatment services through advanced therapeutic protocols that improve outcomes for patients presenting with medium-sized keloid lesions.

By Patient Demographics: Age Group (Largest) vs. Gender (Fastest-Growing)

In the Keloid Treatment Market, age groups represent a significant segment holding market share of 67%, with younger populations often experiencing higher incidences of keloids. Young adults and teenagers are the largest demographics seeking treatment due to the frequency of skin injuries and surgeries that can lead to keloid formation. Meanwhile, the gender segment is gaining traction, with an increasing number of males seeking treatment options, which has contributed to its position as the fastest-growing demographic in recent years.

Sientra (US) continues investing in patient-centered aesthetic treatment innovations supporting younger adults seeking reconstructive and scar revision procedures.

By Distribution Channel: Hospitals (Largest) vs. Dermatology Clinics (Fastest-Growing)

In the Keloid Treatment Market, Hospitals dominate the distribution channel landscape, holding the largest market share of 56%. These institutions provide comprehensive treatment options and have the capacity for advanced surgical interventions, which significantly contributes to their leading position. On the other hand, Dermatology Clinics have emerged as a vital player in this segment, offering specialized services for keloid treatment, which has allowed them to capture a significant portion of the market and cater effectively to a targeted patient demographic.

Hospitals (Dominant) vs. Dermatology Clinics (Emerging)

Hospitals are the dominant distribution channel in the Keloid Treatment Market, recognized for their extensive resources, including state-of-the-art facilities and skilled medical professionals. They provide a wide range of treatment options from surgical removal to advanced laser therapies. Conversely, Dermatology Clinics are emerging as a preferred choice among patients, offering personalized care in a more accessible environment. These clinics facilitate focused attention on skin-related treatments and foster patient-provider relationships, which enhance patient outcomes and satisfaction. As a consequence, Dermatology Clinics are expanding rapidly, driven by the increasing demand for specialized keloid treatment services.

By End User: Healthcare Providers (Largest) vs. Patients (Fastest-Growing)

The Keloid Treatment Market is witnessing a diverse distribution among its end user segments, primarily dominated by Healthcare Providers with market share of 73%. This segment encompasses a wide range of professionals, including dermatologists and plastic surgeons, who are essential in administering treatment options for keloids. Patients, while a smaller but significant part of this market, are increasingly driving growth as awareness and accessibility of treatment options expand. This dynamic interplay reinforces the vital role of Healthcare Providers while highlighting the growing significance of Patients in the treatment landscape.

Healthcare Providers (Dominant) vs. Patients (Emerging)

Healthcare Providers hold a dominant position in the Keloid Treatment Market as they are the primary facilitators of keloid management, offering services ranging from consultation to advanced treatment options. Their expertise and availability greatly influence patient access to care. Conversely, the Patients segment is emerging strongly, driven by heightened awareness around keloid treatments and the availability of advanced therapies. This shift indicates that as more individuals seek treatment for keloids, their role in the market will become increasingly pivotal, thus indicating changing dynamics where patient advocacy and choices will further shape treatment options.

Get more detailed insights about Keloid Treatment Market
Request Free Sample

Regional Insights

North America : Market Leader in Keloid Treatment

North America leads in the Keloid Treatment Market Size, accounting for over 45.87% of the global revenue in 2024. The region's growth is driven by increasing awareness of keloid treatments, advancements in medical technology, and supportive regulatory frameworks. The demand for effective treatment options is further fueled by a rising incidence of keloids, particularly among individuals with darker skin tones, necessitating innovative solutions.

  • According to the CDC, approximately 48 million surgical inpatient procedures and ambulatory surgeries are performed annually in the United States,

The competitive landscape in North America is robust, featuring key players such as Keloid Solutions, Sientra, and Revance Therapeutics. The U.S. stands out as the leading country, supported by a strong healthcare infrastructure and significant investment in research and development. The presence of established companies and emerging startups fosters a dynamic environment for innovation, ensuring a steady supply of advanced treatment options for patients.

  • GE HealthCare invests approximately USD 1 billion annually in research and development, supporting advanced diagnostic imaging and precision healthcare technologies that improve dermatological treatment planning and patient care.

Europe : Emerging Market with Growth Potential

Europe Keloid Treatment Market was valued at USD 0.9 Million in 2024, making it the second-largest regional market with a 27.52% share. The region's growth is driven by increasing healthcare expenditure, a rising prevalence of skin disorders, and a focus on aesthetic treatments. Regulatory bodies are also playing a crucial role in facilitating market entry for new therapies, enhancing patient access to innovative solutions. The demand for personalized medicine is expected to further propel market growth in the coming years.

  • The European Medicines Agency (EMA) coordinates medicine evaluation across 27 EU Member States, strengthening regulatory support for innovative dermatology therapies and improving patient access to advanced scar treatment solutions.

Leading countries in Europe include Germany, France, and the UK, where healthcare systems are increasingly adopting advanced treatment modalities. The competitive landscape features key players like Galderma and Bausch Health, which are investing in research to develop effective keloid treatments. The presence of a well-established healthcare infrastructure and a growing emphasis on dermatological care are key factors driving the market forward.

Asia-Pacific : Rapidly Growing Market Segment

The Asia-Pacific region is emerging as a significant player in the Keloid Treatment Market, with a market size of $0.7 billion in 2024. Factors contributing to this growth include increasing awareness of skin health, rising disposable incomes, and a growing population seeking aesthetic improvements. Regulatory support for new treatment options is also enhancing market dynamics, making advanced therapies more accessible to patients across the region.

Countries like Japan, South Korea, and Australia are leading the charge in adopting innovative keloid treatments. The competitive landscape is characterized by both local and international players, including Medytox and Hugel, who are actively developing new solutions. The region's diverse demographics and varying skin types present unique opportunities for tailored treatment approaches, further driving market expansion.

Middle East and Africa : Emerging Market with Unique Challenges

The Middle East and Africa represent an emerging market for keloid treatments, with a market size of $0.17 billion in 2024. The growth in this region is driven by increasing healthcare investments, a rising awareness of skin conditions, and a growing demand for cosmetic procedures. However, challenges such as limited access to advanced healthcare facilities and varying regulatory environments can hinder market growth.

Efforts to improve healthcare infrastructure are essential for unlocking the region's full potential. Countries like South Africa and the UAE are at the forefront of adopting keloid treatments, with a focus on enhancing patient care. The competitive landscape includes both local and international players, although the market remains fragmented. Key players are beginning to explore partnerships and collaborations to expand their reach and improve treatment accessibility, paving the way for future growth.

Keloid Treatment Market Regional Image

Key Players and Competitive Insights

The Keloid Treatment Market is currently characterized by a dynamic competitive landscape, driven by increasing awareness of keloid conditions and advancements in treatment methodologies. Key players such as Medytox (KR), Keloid Solutions (US), and Revance Therapeutics (US) are strategically positioning themselves through innovation and partnerships. Medytox (KR) focuses on developing novel biologics, while Keloid Solutions (US) emphasizes patient-centric approaches, including personalized treatment plans. Revance Therapeutics (US) is leveraging its expertise in neuromodulators to explore new therapeutic avenues for keloid management.
 
Collectively, these strategies contribute to a competitive environment that is increasingly focused on innovation and patient outcomes.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. This fragmentation allows for diverse treatment options, but also intensifies competition among key players, as they seek to differentiate themselves through unique offerings and improved patient experiences.
 
In November Keloid Solutions (US) announced a partnership with a leading dermatology clinic to enhance its clinical trial capabilities. This collaboration is expected to accelerate the development of its proprietary keloid treatment, potentially positioning the company as a frontrunner in the market. The strategic importance of this partnership lies in its ability to provide real-world data, which could significantly bolster the efficacy claims of Keloid Solutions' products.
 
In October Revance Therapeutics (US) launched a new formulation of its keloid treatment, which incorporates advanced delivery systems to improve patient compliance. This innovation is likely to enhance the therapeutic outcomes for patients, thereby strengthening Revance's market position. The introduction of this formulation reflects a broader trend towards integrating technology into treatment protocols, which may redefine patient engagement in keloid management.
 
In September Bausch Health (CA) expanded its product line by acquiring a small biotech firm specializing in keloid therapies. This acquisition is anticipated to enhance Bausch's portfolio and provide access to novel treatment modalities. The strategic move underscores the importance of mergers and acquisitions in fostering innovation and expanding market reach within the keloid treatment sector.
 
As of December current competitive trends indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, as companies strive to meet the growing demand for effective keloid treatments.

Key Companies in the Keloid Treatment Market include

Industry Developments

POETYK PSO-2, the second pivotal Phase III clinical trial assessing deucravacitinib, a new, selective tyrosine kinase 2 inhibitor for the treatment of patients with moderate to severe plaque psoriasis, was published in February 2021 by Bristol Myers Squibb Company.

POETYK PSO-2 looked at deucravacitinib 6 mg once a day and found that it met both co-primary objectives, with considerably more patients reaching Psoriasis Area and Severity Index (PASI 75). JUBLIA (efinaconazole) topical solution for the treatment of onychomycosis was approved by the US Food and Drug Administration (FDA) in April 2020 for Bausch Health Companies Inc. and its dermatology business Ortho Dermatologics in Keloid Treatment Market

Intended Audience

  • Manufacturers and Suppliers
  • Dermatology Hospitals and Clinics
  • Dermatology laboratories and associations
  • Research and development centers

 

Future Outlook

Keloid Treatment Market Future Outlook

The Keloid Treatment Industry size is projected to reach USD 6.69 Million by 2035, growing at a CAGR of 6.67%, driven by increasing awareness, technological advancements, and rising demand for effective treatments.

New opportunities lie in:

  • Development of personalized keloid treatment regimens Expansion of telemedicine platforms for remote consultations Investment in advanced laser therapy technologies

By 2035, the Keloid Treatment Market is expected to achieve substantial growth and innovation.

Market Segmentation

Keloid Treatment Market End User Outlook

  • Patients
  • Healthcare Providers
  • Research Institutions

Keloid Treatment Market Keloid Size Outlook

  • Small Keloids
  • Medium Keloids
  • Large Keloids
  • Giant Keloids

Keloid Treatment Market Treatment Type Outlook

  • Surgical Excision
  • Intralesional Steroid Injection
  • Cryotherapy
  • Laser Therapy
  • Radiation Therapy

Keloid Treatment Market Distribution Channel Outlook

  • Hospitals
  • Dermatology Clinics
  • Online Pharmacies
  • Retail Pharmacies

Keloid Treatment Market Patient Demographics Outlook

  • Age Group
  • Gender
  • Ethnicity
  • Skin Type

Report Scope

MARKET SIZE 2024 3.27(USD Million)
MARKET SIZE 2025 3.53(USD Million)
MARKET SIZE 2035 6.69(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 6.67% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Medytox (KR), Keloid Solutions (US), Sientra (US), Revance Therapeutics (US), Bausch Health (CA), MediWound (IL), Hugel (KR), Galderma (CH), Evolus (US)
Segments Covered Treatment Type, Keloid Size, Patient Demographics, Distribution Channel, End User
Key Market Opportunities Advancements in minimally invasive techniques enhance patient outcomes in the Keloid Treatment Market.
Key Market Dynamics Rising demand for innovative therapies drives competition and regulatory scrutiny in the keloid treatment market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the projected market valuation of the Keloid Treatment Market by 2035?

The Keloid Treatment Market is projected to reach a valuation of 6.69 USD Million by 2035.

What was the market valuation of the Keloid Treatment Market in 2024?

In 2024, the Keloid Treatment Market was valued at 3.27 USD Million.

What is the expected CAGR for the Keloid Treatment Market during the forecast period 2025 - 2035?

The expected CAGR for the Keloid Treatment Market during the forecast period 2025 - 2035 is 6.67%.

Which treatment type generated the highest revenue in the Keloid Treatment Market?

Intralesional Steroid Injection generated the highest revenue, with a valuation range of 1.0 to 2.0 USD Million.

How do keloid sizes impact the market valuation for treatments?

The market valuation for treatments varies by keloid size, with large keloids generating 1.2 to 2.4 USD Million.

What are the key distribution channels for Keloid Treatment products?
Key distribution channels include hospitals, dermatology clinics, online pharmacies, and retail pharmacies.
Which demographic factors are considered in the Keloid Treatment Market?
Demographic factors include age group, gender, skin type, and ethnicity, with ethnicity showing a valuation range of 1.17 to 2.4 USD Million.
Who are the leading companies in the Keloid Treatment Market?
Leading companies in the Keloid Treatment Market include Bristol-Myers Squibb, Merck & Co., and Pfizer Inc.
What is the revenue range for cryotherapy in the Keloid Treatment Market?
Cryotherapy has a revenue range of 0.5 to 1.0 USD Million in the Keloid Treatment Market.
What is the projected revenue for healthcare providers in the Keloid Treatment Market?
The projected revenue for healthcare providers is expected to range from 1.31 to 2.66 USD Million.
Author
Author
Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get In Touch

Research Approach

 

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO) Global Health Observatory, American Academy of Dermatology (AAD), American Society for Dermatologic Surgery (ASDS), International Wound Infection Institute (IWII), European Academy of Dermatology and Venereology (EADV), EU Eurostat Health Database, and national health ministry reports from key markets. These sources were used to collect treatment statistics, regulatory approval data, clinical safety studies, demographic trends, and market landscape analysis for surgical excision, intralesional steroid injections, cryotherapy, laser therapy, radiation therapy, and emerging biologic treatments.

 

Primary Research

In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of Product Development, heads of regulatory affairs, and commercial directors from OEMs, pharmaceutical firms, and manufacturers of keloid treatment devices were examples of supply-side sources. Board-certified dermatologists, plastic surgeons, wound care experts, medical spa medical directors, and procurement leads from hospitals, dermatology clinics, specialty wound care centers, and cosmetic treatment facilities were among the demand-side sources. Primary research obtained information on clinical adoption trends, pricing tactics, and reimbursement dynamics in addition to validating market segmentation and product pipeline deadlines.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

 

Market Size Estimation

Global market valuation was derived through revenue mapping and treatment volume analysis. The methodology included:

Identification of 40+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America

Product mapping across surgical excision devices, intralesional steroid formulations, cryotherapy equipment, laser therapy systems, radiation therapy devices, and emerging biologic therapies

Analysis of reported and modeled annual revenues specific to keloid treatment portfolios

Coverage of manufacturers representing 70-75% of global market share in 2024

Extrapolation using bottom-up (treatment volume × ASP by country) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.